Portal de Periódicos da CAPES

Managing Asthma in the 21st Century: The Role of Pharmacogenetics

2006; Elsevier BV; Volume: 35; Issue: 9 Linguagem: Inglês

10.3928/0090-4481-20060901-10

1938-2359

Michael E. Wechsler,

Pharmacogenetics and Drug Metabolism

Managing Asthma in the 21st Century: The Role of Pharmacogenetics Michael E Wechsler, MD, MMSc, , MD, MMSc Michael E Wechsler, MD, MMSc Pediatric Annals, 2013;35(9):660–669Published Online:September 01, 2006https://doi.org/10.3928/0090-4481-20060901-10Cited by:11View Full TextPDF ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInRedditEmail SectionsMore1. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006; 129(1): 15-26. Google Scholar2. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br Med Bull. 2000;56(4): 1054-1070. Google Scholar3. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of -illness model. J Am Pharm Assoc (Wash). 2001;41(2): 192-199. Google Scholar4. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. Ann Intern Med. 1999;130(6):487-495. Google Scholar5. Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med. 1996;335(12):841-847. Google Scholar6. Wechsler ME, Lehman E, Lazarus SC, et al. Beta- Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med. 2006;173(5):519-526. Google Scholar7. Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol. 2002;109(3):410-418. Google Scholar8. Tantisira KG, Lake S, Silverman ES, et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHRl with improved lung function in asthmatics treated with inhaled corticosteroids. Hum MoI Genet. 2004;13(13):1353-1359. Google Scholar9. Israel E, Banerjee TR, Fitzmaurice GM, et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med. 2001;345(13):941-947. Google Scholar10. Lima JJ, Zhang S, Grant A, et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med. 2006;173(4):379-385. Google Scholar11. Liggett SB. Polymorphisms of the beta2-adrenergic receptor and asthma. Am J Respir Crit Care Med. 1997;156(4 Pt 2):S 156-S 162. Google Scholar12. Green SA, Cole G, Jacinto M Innis M, Liggett SB. A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem. 1993;268(31):231 16-23121. Google Scholar13. Green SA, Turki J, Bejarano P, Hall IP, Liggett SB. Influence of beta2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell MoI Biol. 1995;13(l):25-33. Google Scholar14. Israel E, Drazen JM, Liggett SB, et al. The effect of polymorphisms of the beta2-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Merf.2000;162(l):75-80. Google Scholar15. Taylor DR, Drazen JM, Herbison GP, et al. Asthma exacerbations during long term beta agonist use: influence of beta2 adrenoceptor polymorphism. Thorax. 20O0;55(9):762-767. Google Scholar16. Litonjua AA, Silverman EK, Tantisira KG, et al. Beta 2-adrenergic receptor polymorphisms and haplotypes are associated with airways hyperresponsiveness among nonsmoking men. Chest. 2004;126(l):66-74. Google Scholar17. Israel E, Chinchilh VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet. 2004;364(9444):1505-1512. Google Scholar18. Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to- moderate asthma. N Engl J Med. 1992;327(20): 1420-1425. Google Scholar19. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet. 1994;344(8917):219-224. Google Scholar20. Bisgaard H. Effect of long-acting beta2 agonists on exacerbation rates of asthma in children. Pediatr P ulmonol. 2O03;36(5):391-398. Google Scholar21. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ. 1993;306(6884): 1034-1037. Google Scholar22. Medwatch Safety Information and Adverse Event Reporting Program: 2003 Safety Alert - Serevent (salmeterol xinafoate). 2003. Food and Drug Administration. Available at: http:// www.fda.gov/medwatch/SAFETY/2003/ serevent.htm. Accessed August 18, 2006. Google Scholar23. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med. 2006;144(12):904-912. Google Scholar24. Drysdale CM, McGraw DW, Stack CB, et al. Complex promoter and coding region beta 2adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA. 2000;97(19): 10483-10488. Google Scholar25. Silverman ES, Breault DT, Vallone J, et al. Corticotropin-releasing hormone deficiency increases allergen-induced airway inflammation in a mouse model of asthma. J Allergy Clin Immunol. 2004;114(4):747-754. Google Scholar26. Finotto S, Neurath MF, Glickman JN, et al. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science. 2002;295(5553):336-338. Google Scholar27. Tantisira KG, Hwang ES, Raby BA, et al. TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci USA. 2004;101(52):18099-18104. Google Scholar28. Drazen JM, Yandava C, Dube L, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet. 1999;22(2): 168-172. Google Scholar29. Lima JJ, Zhang S, Grant A, et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med. 2006; 173(4): 379-385. Google Scholar30. Sampson AP, Siddiqui S, Buchanan D, et al. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafiriukast. Thorax. 2000;55(Suppl 2):S28-S31. Google Scholar31. Asano K Shiomi T, Hasegawa N, et al. Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(I) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics. 2002;12(7):565-570. Google Scholar32. Whelan GJ, Blake K Kissoon N, et al. Effect of montelukast on time-course of exhaled nitric oxide in asthma: influence of LTC4 synthase A(-444)C polymorphism. Pediatr PuImonol. 2003;36(5):413-420. Google Scholar33. Palmer LJ, Silverman ES, Weiss ST, Drazen JM. Pharmacogenetics of asthma. Am J Respir Crit Care Med. 2002;165(7):861-866. Google Scholar34. Silverman EK, Kwiatkowski DJ, Sylvia JS, et al. Family-based association analysis of beta2 -adrenergic receptor polymorphisms in the childhood asthma management program. J Allergy Clin Immunol. 2003;1 12(5): 870-876. Google Scholar35. Weiss ST, Silverman EK, Palmer LJ. Casecontrol association studies in pharmacogenetics. Pharmacogenomics J. 2001; 1(3): 157-158. Google Scholar Previous article Next article FiguresReferencesRelatedDetailsCited by Udwadia Z and Pinto L (2022) LABAs and Asthma: From the SMART Study to the SMART Approach, The Indian Journal of Chest Diseases and Allied Sciences, 10.5005/ijcdas-52-4-191, 52:4, (191-193), Online publication date: 10-Jun-2022. Quizon A, Krone K and Chan M (2020) Asthma Imaging in Pediatric Pulmonology, 10.1007/978-3-030-23979-4_17, (337-347), . Andrzejowski P and Carroll W (2016) Salbutamol in paediatrics: pharmacology, prescribing and controversies, Archives of disease in childhood - Education & practice edition, 10.1136/archdischild-2014-307285, 101:4, (194-197), Online publication date: 1-Aug-2016. Thomsen S (2015) Genetics of asthma: an introduction for the clinician, European Clinical Respiratory Journal, 10.3402/ecrj.v2.24643, 2:1, (24643), Online publication date: 1-Jan-2015. Korbel L, George M and Kitzmiller J (2014) Clinically Relevant Pharmacogenomic Testing in Pediatric Practice, Clinical Pediatrics, 10.1177/0009922814533186, 53:9, (831-838), Online publication date: 1-Aug-2014. Isaza C, Sepúlveda-Arias J, Agudelo B, Arciniegas W, Henao J, Porras G and Beltrán L (2012) β2-adrenoreceptor polymorphisms in asthmatic and non-asthmatic schoolchildren from colombia and their relationship to treatment response, Pediatric Pulmonology, 10.1002/ppul.22521, 47:9, (848-855), Online publication date: 1-Sep-2012. Quizon A (2012) Asthma Imaging in Pediatric Pulmonology, 10.1007/978-1-4419-5872-3_14, (299-305), . Telleria J, Blanco-Quiros A, Varillas D, Armentia A, Fernandez-Carvajal I, Jesus Alonso M and Diez I (2008) ALOX5 promoter genotype and response to montelukast in moderate persistent asthma, Respiratory Medicine, 10.1016/j.rmed.2008.01.011, 102:6, (857-861), Online publication date: 1-Jun-2008. Dijkstra A, Koppelman G, Vonk J, Bruinenberg M, Schouten J and Postma D (2008) Pharmacogenomics and outcome of asthma: No clinical application for long-term steroid effects by CRHR1 polymorphisms, Journal of Allergy and Clinical Immunology, 10.1016/j.jaci.2008.04.015, 121:6, (1510-1513), Online publication date: 1-Jun-2008. Husain A, Loehle J and Hein D (2007) Clinical pharmacogenetics in pediatric patients, Pharmacogenomics, 10.2217/14622416.8.10.1403, 8:10, (1403-1411), Online publication date: 1-Oct-2007. Mo W, Zhang G, Yang T, Dai X, Li H, Zeng H, Liu J, Tan Y, Zhou H and Liu Z The genetic polymorphisms of β3-adrenergic receptor (AR) Trp64Arg and β2-AR Gln27Glu are associated with obesity in Chinese male hypertensive patients, Clinical Chemical Laboratory Medicine, 10.1515/CCLM.2007.089, 45:4 Request Permissions InformationCopyright 2013, SLACK IncorporatedPDF download • 10.2 MB Published online9/01/06